drugset / Trial / NCT00001880

Stem Cell Transplantation for Metastatic Solid Tumors

NCT00001880 ↗

Phase 2 Terminated 42 enrolled National Heart, Lung, and Blood Institute (NHLBI)
NaSingle-groupOpen-labelTreatment

Summary

The goal of this research study is to identify other types of cancer (malignant neoplasms) that may be treatable with stem cell transplantation (allogenic peripheral blood stem cell transplantation. Patients with a variety of different types of cancerous tumors that have spread (metastasized) and whose conditions have not improved with stand therapy, will be eligible to participate. Those patients selected to participate in the study will undergo a procedure known as a "mini-transplant". The mini-transplant is a transplantation of stem-cells collected from a sibling (brother or sister) of the patient. Unlike traditional bone marrow transplants, the mini-transplant does not require intense chemotherapy or radiation therapy. Because of this, patients experience fewer and less severe side effects. This study is open to patients diagnosed with a variety of metastatic solid tumors including esophageal, gastric (stomach), colon, rectal, liver tumors (hepatoma), cancer of the biliary system (cholangiocarcinoma), cancer of the pancreas, lung, breast, prostate, bone (sarcoma), adrenal basal cell, bladder, and adenocarcinomas of unk primary origin.

Timeline

Start
1999-03-12
Primary completion
2008-08-14
Completion
2020-08-13

Outcome

Outcome not reported

Stopped (Enrollment): “Study was closed early due to lack of accrual”

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclosporine Peptide — —
Background Methotrexate Small molecule — Intravenous